The global byler disease market size was valued at USD 1.47 billion in 2025 and is projected to grow from USD 1.55 billion in 2026 to USD 2.35 billion by 2034, registering a CAGR of 5.36% during the forecast period (2026-2034). North America dominated the byler disease market with a share of 37.51% in 2025.
Byler disease, also known as progressive familial intrahepatic cholestasis type 1 (PFIC1), is a rare inherited liver disorder affecting bile secretion. Treatment includes IBAT inhibitors, bile acid sequestrants, and nutritional or supportive therapies. These pharmaceutical products are generally classified under HSN Code 3004 (medicaments for therapeutic use) and SIC Code 2834 (pharmaceutical preparations). Specific classifications depend on drug composition and formulation.
The Byler disease market demand is driven by increasing genetic testing, improved disease diagnosis, and growing access to specialized liver treatments. The availability of targeted therapies, including odevixibat and maralixibat, and advancements in pediatric liver care support Byler disease market growth.
Download a Free Sample To learn more about this report,
Adoption of Targeted IBAT Inhibitor Therapies
The Byler disease market analysis shows increasing adoption of ileal bile acid transporter (IBAT) inhibitors for managing cholestatic pruritus. These therapies reduce bile acid reabsorption and provide targeted treatment for patients with progressive familial intrahepatic cholestasis. Their availability is expanding treatment options beyond conventional medications. For example, Ipsen’s Bylvay (odevixibat) demonstrated significant reductions in serum bile acids and itching symptoms in clinical studies involving PFIC patients.
Increasing Focus on Genotype-Based Treatment Selection
Genetic testing is becoming increasingly important in identifying specific forms of progressive familial intrahepatic cholestasis, including Byler disease. Identification of ATP8B1 mutations helps clinicians confirm PFIC1 and select suitable treatment approaches. This trend supports more personalized management and improved patient monitoring. The growing clinical use of genetic diagnosis also helps differentiate patients who may benefit from targeted medicines or surgical interventions.
Supply chain disruptions are expected to have a moderate impact on the Byler disease market share, given its dependence on specialized pharmaceutical manufacturing, active pharmaceutical ingredients, and international drug distribution. The market is expected to experience a K-shaped recovery as established pharmaceutical companies maintain supply through strong manufacturing and distribution networks. Smaller manufacturers may face higher production costs and treatment delivery delays. The market is projected to grow at a CAGR of 5.36%. Supply constraints could temporarily reduce growth by approximately 1.3 percentage points to 4.0%. Improved drug availability and stable distribution networks are expected to restore market growth to 5.36%.
The Byler disease market is witnessing investment activity through rare liver disease drug development and pharmaceutical financing. In January 2026, Mirum completed private placement financing to support clinical development and commercialization. The funding worth USD 268.5 million primarily targets hepatitis D development rather than Byler disease.
Increasing Genetic Diagnosis of Rare Pediatric Liver Disorders and High Dependence on Specialized Nutritional Therapy Drives Market
The increasing use of genetic testing for pediatric cholestatic disorders is strengthening demand for Byler disease treatments. Genetic screening helps identify ATP8B1 mutations and distinguish PFIC1 from other inherited liver conditions. According to the NIH, progressive familial intrahepatic cholestasis affects approximately 1 in 50,000 to 100,000 individuals. Improved diagnostic accuracy supports earlier patient identification and increases access to disease-specific treatment, contributing to market growth.
High prevalence of fat malabsorption and nutritional deficiencies among Byler disease patients is increasing demand for specialized supportive therapies. Impaired bile secretion limits the absorption of essential nutrients and affects childhood growth. Patients often require long-term supplementation with vitamins A, D, E, and K. According to the National Institutes of Health (NIH) GeneReviews, medium-chain triglyceride formulations are also recommended for managing growth failure, supporting sustained demand for nutritional treatment products.
Treatment-Related Safety Risks and Dependence on Surgical Intervention Restrict Commercial Expansion
Risk of treatment-related complications is limiting the adoption of targeted medicines for Byler disease. IBAT inhibitors may cause diarrhea, liver function abnormalities, and fat-soluble vitamin deficiencies. According to the U.S. Food and Drug Administration (FDA), Bylvay requires regular liver function monitoring and assessment of vitamin levels during treatment. Severe adverse effects may require dose interruption or discontinuation. These safety concerns can restrict treatment eligibility and limit wider market expansion.
The need for surgical intervention in advanced Byler disease cases limits the long-term use of pharmaceutical treatments. Patients with progressive liver damage may require biliary diversion or liver transplantation when medication cannot adequately control disease progression. According to NIH GeneReviews, severe ATP8B1 deficiency often requires surgical management because conventional pharmacotherapy cannot prevent advanced liver complications. This dependence on surgical procedures restricts the commercial potential of disease-specific medicines and limits pharmaceutical market expansion.
Patient-Derived Organoid Technology and Development of Age-Appropriate Pediatric Drug Formulations Offer Growth Opportunities
Advancements in patient-derived organoid technology offer opportunities for developing mutation-specific Byler disease treatments. These laboratory models replicate key features of liver and intestinal tissues affected by ATP8B1 gene mutations. The technology enables pharmaceutical companies to evaluate drug responses and identify potential therapeutic targets. Its ability to support personalized drug screening may reduce dependence on conventional testing methods and create opportunities for developing more effective disease-specific therapies.
Age-appropriate medicines creates opportunities for pharmaceutical companies in the Byler disease market. Infants and young children require formulations that support accurate dosing and easier administration. According to the U.S. Food and Drug Administration (FDA), Bylvay oral pellets are intended for patients weighing below 19.5 kg, while capsules are intended for heavier patients. These requirements create opportunities for weight-based dosing solutions and improved pediatric formulations, supporting treatment accessibility and market expansion.
In 2025, PFIC2 had a share of 22.8%, owing to its early presentation and frequent need for specialist liver management. ABCB11-related bile salt export failure creates sustained demand for disease monitoring and medical intervention during early childhood.
The atypical PFIC is likely to witness a CAGR of 5.91% during the forecast period, supported by improved identification of uncommon genetic variants. Recognition of milder and later-onset disease forms increases the population requiring specialized treatment.
Request Customizationto receive a tailored report.
IBAT inhibitors led the treatment type segment with a share of 31.84% in 2025. This growth is driven by increasing demand for targeted treatment of cholestatic pruritus. Growing preference for non-surgical disease management and wider use of pediatric oral therapies support segment growth.
The antipruritics is anticipated to record a growth rate of 5.19% during the forecast period, owing to continued demand for symptomatic itching management. Persistent cholestatic pruritus creates a need for supportive medication alongside disease-directed treatments in affected patients.
Hospital pharmacy dominated the distribution channel segment in 2025, accounting for a share of 57.64%., due to centralized procurement of specialty medicines and established hospital dispensing networks. Direct access to prescription-only therapies supports the segment's strong distribution position.
Online pharmacy is projected to grow at a CAGR of 6.82% during the forecast period, driven by increasing availability of specialty medicines through licensed digital pharmacies. Home delivery services and recurring prescription fulfillment support channel growth.
Speak to an Analystto discuss market opportunities.
The North America byler disease market accounted for the largest regional share of 37.51% in 2025.
U.S. Byler Disease Market
The U.S. Byler disease market benefits from the availability of prescription therapies for managing progressive familial intrahepatic cholestasis. The United States Food and Drug Administration lists Bylvay for treating pruritus in PFIC patients aged three months and older. Weight-based oral dosing supports treatment across pediatric age groups. Specialized hepatology services and continued prescription requirements support demand for disease-specific medicines and pharmaceutical distribution nationwide.
Canada Byler Disease Market
Canadian market is supported by established prescription drug distribution and access to specialized liver disease medicines. Health Canada's Drug Product Database lists four marketed strengths of Bylvay containing odevixibat. The available strengths range from 200 to 1,200 micrograms. These formulations support weight-based treatment requirements, while specialized pediatric healthcare services provide an established pathway for managing affected patients requiring continuous medical supervision.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific byler disease market is expected to grow at a CAGR of 7.10% during the forecast period, showcasing the fastest-growing regional market.
ChinaByler Disease Market
Ren Ji Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, has documented liver transplantation services for patients with progressive familial intrahepatic cholestasis. The availability of molecular diagnostic testing supports accurate disease identification. These capabilities strengthen demand for specialized pharmaceuticals and long-term treatment management across China.
India Byler Disease Market
Ministry of Health and Family Welfare has identified 12 Centres of Excellence for managing rare diseases across India. These institutions provide specialized healthcare capabilities relevant to inherited liver disorders. The National Policy for Rare Diseases also supports diagnostic and treatment access, creating opportunities for specialized medicines and supportive care products.
Japan Byler Disease Market
The Japanese market is supported by increasing availability of targeted therapies and established pediatric liver treatment facilities. According to Jadeite Medicines, approximately 100 patients in Japan are estimated to have progressive familial intrahepatic cholestasis. The National Center for Child Health and Development provides specialized pediatric liver care and transplantation services. These treatment capabilities support demand for prescription medicines and long-term disease management.
The Europe byler disease market is expected to grow at a CAGR of 5.01% during the forecast period.
UK Byler Disease Market
National Institute for Health and Care Excellence recommends odevixibat for eligible PFIC patients aged six months and older. Its assessment identifies three specialist centers managing PFIC in England. Centralized specialist care and established medicine funding arrangements support treatment accessibility and demand for targeted pediatric liver therapies.
Germany Byler Disease Market
Federal Joint Committee evaluates odevixibat under Germany's pharmaceutical benefit assessment framework for progressive familial intrahepatic cholestasis. This process establishes a formal basis for assessing therapeutic benefits within the healthcare system. Statutory health insurance arrangements and specialist prescribing requirements influence access to targeted medicines, supporting organized pharmaceutical demand for eligible patients.
The Latin America byler disease market is expected to grow at a CAGR of 4.92% during the forecast period. Brazil's Ministry of Health reports 61 authorized rare disease healthcare services across 15 states, supporting access to genetic diagnosis and specialist care. Argentina's Garrahan Hospital provides pediatric liver transplantation services and identifies familial intrahepatic cholestasis among conditions requiring transplantation. These facilities support demand for prescription medicines and long-term disease management across the region.
The Middle East & Africa byler disease market is expected to grow at a CAGR of 4.71% during the forecast period.
Saudi Arabia's King Faisal Specialist Hospital and Research Centre provides pediatric liver disease management and transplant services for patients with inherited cholestatic disorders. The need for long-term nutritional support and management of cholestatic itching creates opportunities for specialized pharmaceutical treatments across the region.
In the UAE, Cleveland Clinic Abu Dhabi offers genetic liver disease evaluation and liver transplantation services. These healthcare capabilities support demand for specialized pharmaceutical treatments and long-term disease management across the region.
The Byler disease market competitive landscape is highly consolidated, with competition comprising global specialty pharmaceutical companies, drug developers, and specialist treatment providers. Key players such as Mirum Pharmaceuticals, Ipsen, Takeda, OrphanPacific, Mirum and Ipsen accounted for approximately 75% of the global byler market share.
Established players compete primarily on regulatory approvals, clinical effectiveness, geographic expansion, and physician engagement. Emerging players in the Byler disease market ecosystem emphasize precision medicines, gene based therapies, and improved long-term patient outcomes.
August 2026: OrphanPacific received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) to expand Buphenyl treatment to progressive familial intrahepatic cholestasis types 1 and 2, including Byler disease.
September 2025: Ipsen received Japanese regulatory approval for Bylvay (odevixibat) to treat pruritus associated with progressive familial intrahepatic cholestasis, expanding treatment options for patients with rare genetic liver disorders.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Experts
The Straits Research Team is a group of experienced researchers, analysts, and industry professionals dedicated to delivering reliable, insightful, and well-structured market intelligence. With expertise across multiple sectors and domains, the team combines extensive research, data analysis, and industry knowledge to provide a clear understanding of evolving markets and business environments.
The team focuses on identifying key market trends, emerging opportunities, technological developments, competitive landscapes, and changing industry dynamics. Through a thoughtful and research-driven approach, it aims to provide valuable insights that help businesses, investors, and decision-makers better understand their industries and make informed strategic decisions.
Asbestosis Treatment Market Size, Forecast, Demand, 2034
Brain Tumor Treatment Market Size, Forecast, Demand, 2034
Ibuprofen Market Size, Share, Growth, Analysis, Report, 2034
Medical Aesthetics Market Size, Share, Growth, Analysis, 2034
Complement Inhibitors Market Size, Share, Growth, Analysis, 2034
Antidiabetics Market Size, Forecast, Demand, Opportunities, 2034
We are featured on:
sales@straitsresearch.com